🇺🇸 FDA
Pipeline program

Placebo to AIN457 150 mg/1 mL Solution for injection in pre-filled syringe, SECUKINUMAB

CAIN457I2401

Approved small_molecule active

Quick answer

Placebo to AIN457 150 mg/1 mL Solution for injection in pre-filled syringe, SECUKINUMAB for non-radiographic axial spondyloarthritis is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
non-radiographic axial spondyloarthritis
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials